LZIC

Across TCGA pan-cancer cohorts, LZIC mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated LZIC data layer compared with 25 for mass-spec protein.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher LZIC mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated LZIC expression acts as an unfavorable survival marker, although some lineages such as PDAC and LUAD show a favorable association.

PDAC and LUAD are the cancer types where LZIC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.902	0.590	.002	41	view →
LUAD	DFS	Median	II,III,IV	0.869	0.209	<.001	24	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

LZIC–PDAC (DFS)

Open the PDAC breakdown →